By SPC News Staff
Due to “disabling side effects,” the FDA updated its safety warning and advises health care providers to restrict fluoroquinolone antibiotic use to certain uncomplicated infections.
The FDA approved changes to the labels of fluoroquinolone antibacterial drugs for systemic use. These medicines are associated with disabling and potentially permanent side effects on the tendons, muscles, joints, nerves and central nervous system that can occur together in the same